相关实验视频

Updated: Jul 17, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

一种可以通过STING途径激活的对比剂,用于MRI引导的瘤免疫扩散突变协同疗法

Shuai Guo¹, Wei Xiong², Jiaoyang Zhu¹

¹School of Biomedical Engineering, Southern Medical University, 1023 Shatai South Road, Guangzhou, Guangdong, 510515, China.

|September 2, 2023

概括

这项研究引入了用于MRI导向癌症治疗的新型纳米粒子,结合免疫疗法和铁灭菌来克服治疗局限性并增强瘤细胞死亡. 新药在临床前模型中显示出有希望的结果.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
癌症治疗癌症治疗

背景情况:

免疫疗法和铁灭症面临着诸如瘤特异性和抵抗机制差等局限性.
干扰素基因刺激剂 (STING) -可激活药物和铁灭抑制剂需要改善输送和有效性.

研究的目的:

开发一种新的纳米粒子用于磁共振成像 (MRI) 引导的协同效应的免疫铁灭疗法.
克服当前免疫疗法和铁灭症治疗的局限性.

主要方法:

开发FeGd-HN@TA-Fe2+-SN38纳米粒子来激活STING通路.
在体内MRI追踪和评估4T1瘤携带小鼠的治疗疗效.
对活性氧物种 (ROS),脂质过氧化物 (LPO),GPX4,SLC7A11,免疫细胞透和细胞因子水平的分析.

主要成果:

FeGd-HN@TA-Fe2+-SN38纳米粒子在体内MRI表现出色,这是由于瘤积累和纳米粒子特性.
这些纳米颗粒有效诱导了协同效应的免疫-铁灭疗法,在小鼠中显示出显著的抗瘤效应.
机制研究证实了增强的STING通路激活,免疫细胞成熟和ferroptosis诱导.

结论:

FeGd-HN@TA-Fe2+-SN38纳米颗粒为MRI导向的协同瘤免疫-费洛托斯疗法提供了一个有前途的平台.
这种方法有效地克服了治疗耐药性,并增强了抗瘤免疫力.
开发的纳米粒子显示了未来在癌症治疗中临床转化潜力.

关键词:

对比剂 (CA) 是一种对比剂.增强的铁灭症治疗疗法免疫性ferroptosis协同疗法的协同疗法.磁共振成像 (MRI) 是一种磁共振成像.干扰素基因 (STING) 的刺激器

更多相关视频

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.